British Journal of Cancer - Table of Contents alert Volume 106 Issue 10

TABLE OF CONTENTS Volume 106, Issue 10 (1581-1712) Published online 8 May 2012 In this issue Editorial Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Also new today Advance online publication Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Want your research freely accessible to all readers immediately on publication? BJC OPEN is available to all authors of original research papers that are accepted for publication in British Journal of Cancer (by paying a one off fee). For further information about BJC OPEN, please see the BJC OPEN FAQs.   Editorial Top Towards individualisation of treatment in endometrial cancer S E Taylor and J A Green Br J Cancer 2012 106: 1581-1582; 10.1038/bjc.2012.140 Full Text Clinical Studies Top Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma C M M Prado, T Bekaii-Saab, L A Doyle, S Shrestha, S Ghosh, V E Baracos and M B Sawyer Br J Cancer 2012 106: 1583-1586; advance online publication, April 17, 2012; 10.1038/bjc.2012.144 Abstract | Full Text Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α S Patil, R A Figlin, T E Hutson, M D Michaelson, S Negrier, S T Kim, X Huang and R J Motzer Br J Cancer 2012 106: 1587-1590; 10.1038/bjc.2012.149 Abstract | Full Text Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer J-C Jo, J-L Lee, M-H Ryu, H M Chang, M Kim, H J Lee, H-S Kim, J-G Shin, T-W Kim and Y-K Kang Br J Cancer 2012 106: 1591-1597; advance online publication, April 19, 2012; 10.1038/bjc.2012.143 Abstract | Full Text A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours D S Boss, H Glen, J H Beijnen, M Keesen, R Morrison, B Tait, W Copalu, A Mazur, J Wanders, J P O'Brien, J H M Schellens and T R J Evans Br J Cancer 2012 106: 1598-1604; advance online publication, April 19, 2012; 10.1038/bjc.2012.154 Abstract | Full Text The dynamic change of circulating tumour cells in patients with operable breast cancer before and after chemotherapy based on a multimarker QPCR platform M-h Chong, Y Zhao, J Wang, X-m Zha, X-a Liu, L-j Ling, Q Du and S Wang Br J Cancer 2012 106: 1605-1610; advance online publication, April 19, 2012; 10.1038/bjc.2012.157 Abstract | Full Text The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS M G Wallis, K Clements, O Kearins, G Ball, J Macartney and G M Lawrence Br J Cancer 2012 106: 1611-1617; advance online publication, April 19, 2012; 10.1038/bjc.2012.151 Abstract | Full Text Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer K Ribi, J Aldridge, K-A Phillips, A Thompson, V Harvey, B Thürlimann, F Cardoso, O Pagani, A S Coates, A Goldhirsch, K N Price, R D Gelber and J Bernhard for the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group (IBCSG) Br J Cancer 2012 106: 1618-1625; advance online publication, April 24, 2012; 10.1038/bjc.2012.156 Abstract | Full Text Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials M C Ethier, M Science, J Beyene, M Briel, T Lehrnbecher and L Sung Br J Cancer 2012 106: 1626-1637; 10.1038/bjc.2012.147 Abstract | Full Text Translational Therapeutics Top The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function L C J Baker, J K R Boult, S Walker-Samuel, Y-L Chung, Y Jamin, M Ashcroft and S P Robinson Br J Cancer 2012 106: 1638-1647; advance online publication, April 12, 2012; 10.1038/bjc.2012.131 Abstract | Full Text Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells T Troiani, L Vecchione, E Martinelli, A Capasso, S Costantino, L P Ciuffreda, F Morgillo, D Vitagliano, E D'Aiuto, R De Palma, S Tejpar, E Van Cutsem, M De Lorenzi, M Caraglia, L Berrino and F Ciardiello Br J Cancer 2012 106: 1648-1659; 10.1038/bjc.2012.129 Abstract | Full Text The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction G Descamps, P Gomez-Bougie, J Tamburini, A Green, D Bouscary, S Maïga, P Moreau, S Le Gouill, C Pellat-Deceunynck and M Amiot Br J Cancer 2012 106: 1660-1667; advance online publication, April 17, 2012; 10.1038/bjc.2012.139 Abstract | Full Text Molecular Diagnostics Top Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach M Yoshii, H Tanaka, M Ohira, K Muguruma, T Iwauchi, T Lee, K Sakurai, N Kubo, M Yashiro, T Sawada and K Hirakawa Br J Cancer 2012 106: 1668-1674; advance online publication, April 19, 2012; 10.1038/bjc.2012.141 Abstract | Full Text Incidence and possible pathogenesis of sentinel node micrometastases in ductal carcinoma in situ of the breast detected using molecular whole lymph node assay T Osako, T Iwase, K Kimura, K Masumura, R Horii and F Akiyama Br J Cancer 2012 106: 1675-1681; advance online publication, April 24, 2012; 10.1038/bjc.2012.168 Abstract | Full Text Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome C Krakstad, J Trovik, E Wik, I B Engelsen, H M J Werner, E Birkeland, M B Raeder, A M Øyan, I M Stefansson, K H Kalland, L A Akslen and H B Salvesen Br J Cancer 2012 106: 1682-1688; advance online publication, March 13, 2012; 10.1038/bjc.2012.91 Abstract | Full Text The differential effects of statins on the metastatic behaviour of prostate cancer M Brown, C Hart, T Tawadros, V Ramani, V Sangar, M Lau and N Clarke Br J Cancer 2012 106: 1689-1696; advance online publication, April 24, 2012; 10.1038/bjc.2012.138 Abstract | Full Text Genetics and Genomics Top Germline BRCA1 mutations increase prostate cancer risk D Leongamornlert, N Mahmud, M Tymrakiewicz, E Saunders, T Dadaev, E Castro, C Goh, K Govindasami, M Guy, L O'Brien, E Sawyer, A Hall, R Wilkinson, D Easton, The UKGPCS Collaborators, D Goldgar, R Eeles and Z Kote-Jarai Br J Cancer 2012 106: 1697-1701; advance online publication, April 19, 2012; 10.1038/bjc.2012.146 Abstract | Full Text PPARγ agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells E Pestereva, S Kanakasabai and J J Bright Br J Cancer 2012 106: 1702-1712; advance online publication, April 24, 2012; 10.1038/bjc.2012.161 Abstract | Full Text Advertisement Hot off the press!! Did you know this article from British Journal of Cancer recently appeared in the press? Variation in advanced stage at diagnosis of lung and female breast cancer in an English region 2006-2009 G Lyratzopoulos, G A Abel et al Read this Article now!   Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.